McKesson
Q1 2023 Earnings Call
Aug 03, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Welcome to McKesson's first quarter fiscal 2023 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Rachel Rodriguez, VP of investor relations. Please go ahead.
Rachel Rodriguez -- Vice President, Investor Relations
Thank you, operator. Good afternoon, and welcome, everyone, to McKesson's first quarter fiscal 2023 earnings call. Today, I'm joined by Brian Tyler, our chief executive officer, and Britt Vitalone, our chief financial officer. Brian will lead off, followed by Britt, and then we will move to a question-and-answer session.
Today's discussion will include forward-looking statements such as forecast about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com, and to the risk factors section of our periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements. Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and updated guidance assumptions.
With that, let me turn it over to Brian.
Brian Tyler -- Chief Executive Officer
Thanks, Rachel, and thanks to everyone joining us on our call this afternoon. Earlier today, we announced our first quarter fiscal 2023 results with strong growth in total company revenue and adjusted operating profit across the North American businesses. As a result of our first quarter performance and McKesson's continued role in the COVID-19 response efforts, we are raising our guidance range for fiscal 2023 adjusted earnings per diluted share from $22.90 to $23.60, to a new range of $23.95 to $24.65. Successful execution against our company's priorities, priorities of people and culture, sustainable core growth, streamlining the portfolio, and expanding the oncology and biopharma services ecosystems are really what underpin our fiscal 2023 outlook and our long-term growth framework.
So I wanted to center my remarks today around those themes. And I thought I would start maybe with a highlight of the progress we've made against our company priorities, and then I will wrap up with a few brief comments on the performance in the business itself. Foundational to our company, foundational to our company's history, quite frankly, and our strategy are really the core pharmaceutical and medical distribution businesses. As we expand the reach of our services, we remain focused on generating sustainable growth in these core businesses.